Harry Simeonidis, President and CEO at INBS, commented, "This milestone is an important element of our FDA 510(k) pathway for regulatory clearance, and we are proud to announce its completion. Our development team continues to execute on our plan to meet FDA requirements for our Drug Screening System. We are now poised to move forward with the next stages of our clinical study plan and move closer to bringing our innovative technology to the market." Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medica ...